(Q36123467)

12 August 2017

1 reference

title

Stroke in patients with diabetes and hypertension (English)

1 reference

12 August 2017

Samy I McFarlane

1

1 reference

12 August 2017

Domenic A Sica

series ordinal

2

1 reference

12 August 2017

James R Sowers

series ordinal

3

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Journal of Clinical Hypertension

12 August 2017

published in

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

286-92; quiz 293-4

1 reference

New evidence for stroke prevention: scientific review

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

The confounding of race and geography: how much of the excess stroke mortality among African Americans is explained by geography?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Reducing the risk of stroke in diabetes: what have we learned that is new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Diabetes as a risk factor for stroke. A population perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

High prevalence of undiagnosed diabetes among Chinese patients with ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Treatment of cardiovascular and renal risk factors in the diabetic hypertensive

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

The association of hyperglycemia with cerebral edema in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Insulin resistance and risk for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Stroke prevention: management of modifiable vascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Clinical trials: Evidence and unanswered questions--hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Atrial fibrillation, anticoagulation, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Management of dyslipidemia in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy--a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Primary Prevention of Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

Risk Factors for Stroke in Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04379.X

10.1111/J.1524-6175.2005.04379.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference